A Contemporary Guidelines Over Selumetinib

We agree with the conclusions of Procopio et?al. [1]. In our cancer centre, a similar study has been performed using low-dose ketoconazole therapy for patients with castration-resistant prostate cancer resistant to docetaxel chemotherapy. The key results of our study are listed in Table 1. There was overall disease control in four of 14 patients with a PFS of 2.3?months. The explanation for the discrepancy between our study and the above paper may be the patients�� characteristics (for example, resistant to only docetaxel chemotherapy in our study vs resistant to both docetaxel and mitoxantrone in the above paper [1]) and the different definitions of biochemical progression. After reading the Procopio et?al. [1] paper meticulously, I wanted to have an opportunity to state my viewpoint. First, the definition of biochemical progression should be described more clearly. Ketoconazole therapy had a moderate effect and most patients with a partial response http://www.selleckchem.com/products/MK-1775.html or complete response or stable disease would inevitably progress at 3.2�C8.6?months [2�C4]. Thus, one of the most common definitions used by other ketoconazole studies [2] has been that from the PSA Working Group Consensus Criteria http://www.selleckchem.com/products/AZD6244.html [5], which suggested the definition of PSA progression was either a PSA level increase of 50% above the nadir if a ��50% decline in PSA level had been reached, or a PSA level increase of 25% above the nadir if there is a http://www.selleck.cn/products/azd4547.html description of relevant variables should be given, e.g. an absolute neutrophil count of ��1.5 �� 109/L, platelet count of ��100 �� 109/L, haemoglobin of ��8?g/dL, liver aspartate aminotransferase and alanine aminotransferase levels should be ��2.5-times the upper limit of normal (ULN), bilirubin levels under the ULN and creatinine levels under the ULN [7]. These suggestions might assist the study of ketoconazole or abiraterone in the future. Thus, according to the European Association of Urology Guidelines 2010, androgen synthesis inhibitors, e.g. ketoconazole and abiraterone, play an important role as second- or third-line hormonal management regimens in prostate cancer [8].